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Abstract
Meibomian cell carcinoma (MCC) is a malignant tumor of the meibomian glands located in the eyelids. No information exists on the
cytogenetic and genetic aspects of MCC. There is no report on the gene expression profile of MCC. Thus there is a need, for both scientific and
clinical reasons, to identify genes and pathways that are involved in the development and progression of MCC. We analyzed the gene expression
profile of MCC by the microarray technique. Forty-four genes were upregulated and 149 genes were downregulated in MCC. Differential
expression data were confirmed for 5 genes by semiquantitative RT-PCR in MCC tumors: GTF2H4, RBM12, UBE2D3, DDX17, and LZTS1. We
found dysregulation of two major pathways in MCC: MAPK and JAK/STAT. Clusters of genes on chromosomes 1, 12, and 19 were dysregulated
in MCC. The data presented here will facilitate the identification of specific markers and therapeutic targets for the treatment of MCC patients.
© 2007 Elsevier Inc. All rights reserved.Keywords: Expression profile; Meibomian cell carcinoma; MAPK signaling pathway; JAK/STAT pathway; MicroarraysMeibomian glands are responsible for the maintenance of the
health and integrity of the ocular surface. They promote stability
and prevent evaporation of the preocular tear film through the
synthesis and secretion of lipids at the lid margin [1]. First
described by Meibomius, these oil-producing sebaceous glands
number around 30–40 in the upper and 20–30 in the lower
eyelids [2]. Meibomian cell carcinoma (MCC), also referred to
as sebaceous carcinoma, is a malignant tumor that occurs most
commonly on the eyelids [3]. Although rare, MCC is the fourth
most common tumor among eyelid tumors after basal cell
carcinoma, squamous cell carcinoma, and cutaneous melanomas
[4]. Local recurrence and regional lymph node metastasis are
common in MCC. In addition, this neoplasm has also been
reported to spread to the trigeminal ganglion and cerebellum [5].
The only known therapy for this cancer is the surgical excision of
the tumor, but it reappears after some time following the surgery.
Nothing is known about the cytogenetic and genetic events
involved in the development and progression of this neoplasm.⁎ Corresponding author. Fax: +91 80 2360 0999.
E-mail address: karun@mrdg.iisc.ernet.in (A. Kumar).
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doi:10.1016/j.ygeno.2007.07.008Although microarray analysis has been used extensively to
provide a vast amount of knowledge on cancer etiology and
biomarkers for therapeutic applications by profiling the
transcriptome of many cancers, no microarray analysis has
been done previously on this tumor. The main aim of this study
was to identify genes involved in the tumorigenesis of this
tumor. We report the first gene expression profile of this tumor
using cDNA microarray analysis.
Results
Differential gene expression in MCC
Microarray analysis of MCC yielded a data set with 193
differentially regulated genes. Of these, 44 genes were
upregulated and 149 were downregulated (Supplemental Table
1S). These included genes involved in various cellular functions
such as cell cycle and cell proliferation, signal transduction,
transcription and translation, cell death and apoptosis, enzyme
metabolism, and cell adhesion. Some of the selected genes are
listed in Table 1. Our analysis showed dysregulation of two
Table 1
Selected differentially regulated genes with known function in MCC
Gene Symbol UniGene Chromosome
location
Expt 1 Expt 2 Average
ratio
Cell cycle/cell proliferation
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 DDX17 Hs.528305 22q13.1 0.278 0.201 0.240
Leucine zipper, putative tumor suppressor 1 LZTS1 Hs.521432 8p22 0.453 0.463 0.458
CDK2-associated protein 1 CDK2AP1 Hs.433201 12q24.31 0.374 0.598 0.486
Metallothionein 3 (growth inhibitory factor) MT3 Hs.73133 16q13 0.449 0.532 0.491
Glycoprotein (transmembrane) nmb GPNMB Hs.190495 7p15 0.400 0.583 0.492
DEAD (Asp-Glu-Ala-As) box polypeptide 19 DDX19B Hs.221761 16q22.1 2.197 4.079 3.138
Signal transduction/kinases
Signal transducer and activator of transcription 2 STAT2 Hs.530595 12q13.2 0.301 0.543 0.422
Casein kinase 1, ε CSNK1E Hs.474833 22q13.1 0.273 0.606 0.440
Serum/glucocorticoid-regulated kinase SGK Hs.510078 6q23 0.393 0.567 0.480
Tyrosine 3-mono-oxygenase β polypeptide YWHAB Hs.651212 20q13.1 0.470 0.513 0.492
Neuronal PAS domain protein 3 NPAS3 Hs.659456 14q12–q13 0.418 0.590 0.504
Centaurin, β1 CENTB1 Hs.337242 17p13.1 0.578 0.431 0.505
Amyloid β (A4) precursor protein-binding,
family B, member 2
APBB2 Hs.479602 4p14 0.424 0.590 0.507
Dual-specificity phosphatase 19 DUSP19 Hs.132237 2q32.1 0.402 0.614 0.508
Serine/threonine kinase 38 STK38 Hs.409578 6p21 0.568 0.451 0.510
Phospholipase C, δ4 PLCD4 Hs.632528 2q35 0.539 0.494 0.517
MAP/microtubule affinity-regulating kinase 4 MARK4 Hs.34314 19q13.32 2.577 1.773 2.180
Interleukin 23, α subunit p19 IL23A Hs.98309 12q13.2 1.664 5.726 3.700
Transcription/translation
NSFL1 (p97) cofactor (p47) NSFL1C Hs.12865 20p13 0.304 0.326 0.315
Ribosomal protein S4, X-linked RPS4X Hs.446628 Xq13.1 0.280 0.599 0.440
Nuclear factor of activated T cells 5 NFAT5 Hs.371987 16q22.1 0.516 0.451 0.483
General transcription factor IIH, polypeptide 1 GTF2H1 Hs.577202 11p15.1–p14 0.585 0.461 0.523
Homeobox C9 HOXC9 Hs.658823 12q13.13 0.607 0.470 0.539
BarH-like homeobox 1 BARX1 Hs.164960 9q12 2.335 1.997 2.166
Activating signal cointegrator 1 complex subunit 2 ASCC2 Hs.517438 22q12.1 1.678 2.874 2.276
Polymerase (RNA) II (DNA-directed)
polypeptide E
POLR2E Hs.24301 19p13.3 2.022 3.212 2.617
General transcription factor IIH, polypeptide 4 GTF2H4 Hs.485070 6p21.3 2.549 3.901 3.225
U5 snRNP-specific protein, 116 kDa EFTUD2 Hs.151787 17q21.31 1.789 4.869 3.329
RNA binding motif protein 12 RBM12 Hs.246413 20q11.21 2.701 4.378 3.540
Cell death/apoptosis
Baculoviral IAP repeat-containing 4 BIRC4 Hs.356076 Xq25 0.245 0.507 0.376
Interleukin 24 IL24 Hs.658964 1q32.1 0.289 0.590 0.440
Growth arrest and DNA-damage-inducible, γ GADD45G Hs.9701 9q22 0.437 0.607 0.522
Tumor necrosis factor receptor superfamily,
member 21
TNFRSF21 Hs.443577 6p21.1–p12.2 0.584 0.469 0.527
CD74 antigen CD74 Hs.694723 5q32 2.470 2.227 2.349
Enzyme/metabolism
Ectonucleoside triphosphate diphosphohydrolase 2 ENTPD2 Hs.123036 9q34 0.301 0.210 0.256
Carbonic anhydrase XII CA12 Hs.210995 15q22 0.242 0.419 0.331
Betaine-homocysteine methyltransferase 2 BHMT2 Hs.114172 5q13 0.293 0.442 0.368
N-myristoyltransferase 2 NMT2 Hs.60339 10p13 0.206 0.596 0.401
Carboxypeptidase Z CPZ Hs.78068 4p16.1 0.385 0.489 0.437
Collectin subfamily member 12 COLEC12 Hs.464422 18pter–p11.3 0.302 0.609 0.456
Endo-β-N-acetylglucosaminidase FLJ21865 Hs.29288 17q25.3 0.490 0.456 0.473
Methylenetetrahydrofolate dehydrogenase MTHFD1 Hs.652308 14q24 0.373 0.597 0.485
Histidyl-tRNA synthetase 2 HARS2 Hs.432560 20p11.23 0.528 0.444 0.486
Scavenger receptor class A, member 3 SCARA3 Hs.128856 8p21 0.419 0.565 0.492
Pyruvate dehydrogenase kinase, isoenzyme 3 PDK3 Hs.658190 Xp22.11 1.757 2.907 2.332
Ubiquitin-conjugating enzyme E2D 3 UBE2D3 Hs.518773 4q24 2.139 3.282 2.711
Cell adhesion
Keratin 1 (epidermolytic hyperkeratosis) KRT1 Hs.80828 12q13.13 0.195 0.612 0.404
Periplakin PPL Hs.192233 16p13.3 0.463 0.348 0.406
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Table 1 (continued)
Gene Symbol UniGene Chromosome
location
Expt 1 Expt 2 Average
ratio
Cell adhesion
ARP3 actin-related protein 3 homolog (yeast) ACTR3 Hs.433512 2q14.1 0.470 0.426 0.448
Matrilin 1, cartilage matrix protein MATN1 Hs.150366 1p35.2 0.575 0.396 0.486
Sarcoglycan, ε SGCE Hs.371199 7q21–q22 0.613 0.378 0.496
Tubulointerstitial nephritis antigen TINAG Hs.127011 6p11.2–p12 2.129 1.995 2.062
Beaded filament structural protein 2, phakinin BFSP2 Hs.659862 3q21–q25 2.715 1.839 2.277
Thrombospondin 3 THBS3 Hs.169875 1q22 1.645 3.365 2.505
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(MAPK) and Janus kinase/signal transducers and activators of
transcription (JAK/STAT) (Table 2).
To confirm the microarray results, we performed semiquan-
titative RT-PCR analysis for five genes in a panel of four MCC
and two normal eyelid samples: GTF2H4, RBM12, UBE2D3,
DDX17, and LZTS1 (Table 1). The mean mRNA expression
levels of GTF2H4 (0.53±0.01 in normal vs 2.03±0.29 in
tumor, p=0.028), RBM12 (0.47±0.13 in normal vs 1.75±0.30
in tumor, p=0.049), and UBE2D3 (0.52±0.01 in normal vs
1.60±0.18 in tumor, p=0.017) were significantly greater in
tumor samples compared with the expression levels in normal
samples (Fig. 1). The mean expression levels of DDX17 (2.43±
0.39 in normal vs 0.93±0.24 in tumor, p=0.027) and LZTS1
(1.99±0.25 in normal vs 0.67±0.15 in tumor, p=0.009) were
significantly lower in tumor samples compared to the expres-
sion levels in normal samples (Fig. 1).
Significant chromosome association
A careful analysis of our data showed clusters of
differentially regulated genes associated with certain chromo-
somes (Fig. 2). For example, we found clusters of genes
associated with chromosomes 1, 12, and 19 to be differentially
regulated in MCC (Fig. 2).
Discussion
To the best of our knowledge, the microarray analysis of
MCC has provided the first ever cataloguing of genes that are
dysregulated in this neoplasm. We have validated the micro-
array data for five genes (viz., GTF2H4, RBM12, UBE2D3,Table 2
Major pathways dysregulated in MCC
Pathway/gene Symbol
MAPK signaling
Growth arrest and DNA-damage-inducible, γ GADD45G
Sterile α motif and leucine zipper-containing kinase AZK ZAK
MAP/microtubule affinity-regulating kinase 4 MARK4
Tumor necrosis factor receptor superfamily, member 21 TNFRSF21
JAK/STAT signaling
Interleukin 24 IL24
Interleukin 23, α subunit p19 IL23A
Signal transducer and activator of transcription 2, 113 kDa STAT2DDX17, and LZTS1) in a panel of four MCC and two normal
eyelid tissues by semiquantitative RT-PCR analysis (Fig. 1).
Nothing is known about the functional relevance of the
GTF2H4 gene. It is a transcription factor that was found to be
upregulated across MCC cases (Fig. 1). Another interesting
gene that was also upregulated in MCC is RBM12 (Fig. 1). This
gene was first isolated from a human colon carcinoma cell line
cDNA library and contains several RNA binding domains [6].
The functional relevance of this gene is unknown and further
analysis may lead to some interesting insights with relevance to
tumorigenesis.
The ubiquitin–proteasome pathway (UPP) is the universal
and highly substrate-specific housekeeping system involved in
the degradation of damaged, aberrant, and expired proteins. A
variety of roles for UPP have been elucidated in cellular
physiology and pathology, including apoptosis [7]. UBE2D3
(ubiquitin-conjugating enzyme E2D3) is one of the components
of the UPP pathway. Upregulation of UBE2D3 has been
reported in oncocytic thyroid tumors by differential display
analysis [8]. Interestingly, UBE2D3 was upregulated in MCC
tumors (Fig. 1).
The DDX17 (DEAD box polypeptide 17) gene is located on
chromosome 22 and encodes an RNA helicase [9]. The p72
(DDX17) is a highly related member of the DEAD box family.
It has been implicated in growth regulation and also shown to be
involved in both pre-mRNA and pre-rRNA processing [9].
Wilson et al. [9] have shown that p68 and p72 interact with
HDAC1 and repress transcription in a promoter-specific
manner. DDX17 was found to be downregulated in MCC
tumors (Fig. 1).
The LZTS1 (leucine zipper, putative tumor suppressor 1)
gene is located on chromosome 8p22 and encodes a protein withUniGene Chromosome
location
Expt 1 Expt 2 Average
ratio
Hs.9701 9q22.1–q22.2 0.437 0.607 0.522
Hs.444451 2q24.2 1.822 3.600 2.711
Hs.34314 19q13.32 2.577 1.773 2.175
Hs.443577 6p21.1–q12.2 0.584 0.469 0.527
Hs.658964 1q32.1 0.289 0.590 0.440
Hs.98309 12q13.2 1.664 5.726 3.695
Hs.530595 12q13.3 0.301 0.543 0.422
Fig. 1. Semiquantitative RT-PCR analysis of five genes in two normal eyelids
and four MCC samples. Each triangle/square represents data from one sample.
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domain of the cAMP-responsive activating transcription factor
5 [10]. Mutations in this gene have been found in primary
esophageal cancers and in a prostate cancer cell line [10]. Ishii
et al. [11] have shown that LZTS1 inhibits cancer cell growth
through regulation of mitosis and that its alterations result in
abnormal cell growth. Reduced expression of this gene was
observed in 27/98 non-small cell lung cancers [12]. The LZTS1
gene is inactivated in many cancers with 8p deletions, including
prostate, esophageal, gastric, bladder, and breast cancers [12].
As expected, it was downregulated in MCC tumors (Fig. 1).Previous study on gene expression profiles of cell lines has
shown that chromosomal modifications can lead to regional bias
in gene expression [13]. When we searched our microarray data
for such regional biases, we found clusters of genes on
chromosomes 1, 12, and 19 to be differentially regulated in
MCC (Supplemental Table 1S, Fig. 2). In addition, clusters of
genes in certain segments of these chromosomes were
differentially regulated. For example, a cluster of five genes
(viz., CD22, PAF1, MARK4, TBCB, and GRIN2D) on chromo-
some segment 19q13.12–q13.32 was differentially regulated in
MCC (Fig. 2). CD22, PAF1, and MARK4 were upregulated,
whereas TBCB and GRIN2D were downregulated (Fig. 2).
Huang et al. [14] have recently found aberrant expression of
CD22 as a useful marker for the detection of monoclonal B
cells admixed with numerous benign polyclonal B cells.
PAF1/PD2 (pancreatic differentiation 2) is the human homolog
of the yeast RNA polymerase II-associated factor 1 (hPaf1).
PAF1 is a nuclear 80-kDa protein, which interacts with RNA
polymerase II [15]. Moniaux et al. [15] have recently
demonstrated that overexpression of PAF1 in NIH 3T3 cells
results in enhanced growth in vitro and tumor formation in vivo.
Using a detailed FISH analysis of the breakpoints of structural
19q chromosome rearrangements in gliomas, Beghini et al. [16]
have identified a 19q13.2 intrachromosomal amplification of
the MARK4 (MAP/microtubule affinity-regulating kinase 4)
gene in three primary glioblastoma cell lines. They observed
that MARK4 is upregulated in both fresh and cultured gliomas
and overexpressed in all of the above three glioblastoma cell
lines. Taken together, the upregulation of CD22, PAF1, and
MARK4 in MCC is not surprising. The status of the other two
downregulated genes (TBCB and GRIN2D) in this cluster is not
known in any other tumor.
The transmission of extracellular signals to their intracellular
targets is mediated by a network of interacting proteins that
regulate a large number of cellular processes. One such
pathway, which involves activation of several signaling
molecules followed by a sequential stimulation of several
cytoplasmic protein kinases, is the MAPK signaling cascade
[17]. Our study found differential expression of a number of
genes involved in this pathway (viz. GADD45G, ZAK, MARK4,
and TNFRSF21). The GADD45G gene is a member of the
MAPK signaling pathway. It is located at the commonly deleted
region 9q22 in multiple tumors [18]. GADD45G (CR6), along
with GADD45A (GADD45) and GADD45B (MyD118),
constitutes a family of evolutionarily conserved, small, acidic,
nuclear proteins, which have been implicated in terminal
differentiation, growth suppression, and apoptosis [19]. In
response to stress shock, GADD45G inhibits cell growth and
induces apoptosis [18]. Vairapandi et al. [19] have shown that
GADD45B and GADD45G specifically interact with the Cdk1/
cyclin B1 complex, but not with other Cdk/cyclin complexes, in
vitro and in vivo. Interaction of GADD45B, GADD45G, and
GADD45A with both Cdk1 and cyclin B1 results in inhibition
of the kinase activity of the Cdk1/cyclin B1 complex [19].
Inhibition of Cdk1/cyclin B1 kinase activity by GADD45B and
GADD45A was found to involve disruption of the complex,
whereas GADD45G did not disrupt the complex [19]. Using
Fig. 2. Associations of differentially expressed genes with chromosomes 1, 12, and 19. Genes are displayed according to their genomic locations. Average log-ratios
(fold changes) are written next to the genes.
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GADD45 RNA, Vairapandi et al. [19] showed that all three
GADD45 proteins are likely to cooperate in the activation of S
and G2/M checkpoints following exposure of cells to UV
irradiation. Similar to other members of the other GADD45
family, GADD45G is ubiquitously expressed in all normal adult
and fetal tissues [18]. However, it shows frequent down-
regulation and promoter hypermethylation in tumor cell lines,
including 11 of 13 (85%) non-Hodgkin lymphoma, 3 of 6
(50%) Hodgkin lymphoma, 8 of 11 (73%) nasopharyngeal
carcinoma, 2 of 4 (50%) cervical carcinoma, 5 of 17 (29%)
esophageal carcinoma, and 2 of 5 (40%) lung carcinoma and
other cell lines, but not in any immortalized normal epithelial
cell line, normal tissue, or peripheral blood mononuclear cells
[18]. The transcriptional silencing of GADD45G is reversed by
5-aza-2′-deoxycytidine treatment or genetic double knockout
of DNMT1 and DNMT3B, indicating a direct epigenetic
mechanism [18]. Aberrant methylation was frequently detected
in primary lymphomas although less frequently in primary
carcinomas [18]. GADD45G could be induced by heat shock
or UV irradiation in unmethylated cell lines [18]. Ying et al.
[18] showed that ectopic expression of GADD45G strongly
suppressed tumor cell growth and colony formation in silenced
cell lines, suggesting that GADD45G can act as a functional
new-age tumor suppressor, but is frequently inactivatedepigenetically in multiple tumors. Chung et al. [20] analyzed
the expression of GADD45G in anaplastic thyroid cancer cell
lines to test the potential utility of the GADD45G gene as a
candidate for gene therapy in anaplastic thyroid cancer, which
is a highly aggressive and extremely lethal form of human
cancer. They found that GADD45G RNA was present at
significantly lower levels in anaplastic cancer cells compared
with normal primary cultured thyrocytes. The adenovirus-
mediated reexpression of GADD45G significantly inhibited
the proliferation of cells in the anaplastic thyroid carcinoma
cell lines due to apoptosis. They suggested that this gene could
be used as a candidate for gene therapy in anaplastic thyroid
cancer. As expected, we found this gene to be downregulated
in MCC (Table 2).
The ZAK gene is another member of the MAPK signaling
pathway. It encodes a protein of 800 amino acids that contains a
kinase catalytic domain, a leucine-zipper, and a sterile-α motif
[21]. Liu et al. [21] found that ZAK activates JNK/SAPK1
(MAPL8) and NFKB, and overexpression of ZAK resulted in
apoptosis in a human hepatoma cell line. We found this gene to
be upregulated in MCC (Table 2).
TNFRSF21 (tumor necrosis factor receptor superfamily,
member 21) or death receptor-6 (DR6) is a member of a
subgroup termed death receptors in the tumor necrosis factor
receptor superfamily. It contains a cytoplasmic death domain.
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programmed cell death. Currently, there are six different death
receptors: tumor necrosis factor (TNF) receptor-1, CD95 (Fas/
APO-1), TNF receptor-related apoptosis-mediating protein
(TRAMP), TNF-related apoptosis-inducing ligand (TRAIL)
receptor-1 and -2, and death receptor-6 (DR6) [22]. The
signaling pathways by which these receptors induce apoptosis
are similar and rely on oligomerization of the receptor by death
ligand binding, recruitment of an adapter protein through
homophilic interaction of cytoplasmic domains, and subsequent
activation of an inducer caspase, which initiates execution of the
cell death program [22]. Exogenous expression of DR6 induced
apoptosis in untransformed or tumor-derived cells [23]. DR6
potently activates JNK [24]. This gene was downregulated in
MCC (Table 2).
The JAK/STAT pathway is an important signaling cascade
that transduces a multitude of signals leading to cell prolifera-
tion, differentiation, cell migration, and apoptosis [25]. In this
study, we found several genes (viz. IL24, IL23A, and STAT2)
belonging to this pathway to be differentially regulated in MCC.
The IL24 gene of this pathway is located on 1q32.1 and was
cloned using a differentiation induction subtraction hybridiza-
tion strategy to identify and clone genes involved in growth
control and terminal differentiation in human cancer cells [26].
This gene is also called as the melanoma differentiation-
associated gene-7 (MDA7) and the suppression of tumorigeni-
city 16 (ST16). Jiang et al. [26] showed that overexpression of
IL24 was growth inhibitory toward diverse human tumor cells.
Huang et al. [27] suggested that it has potential utility for the
gene-based therapy of diverse human cancers. Su et al. [28]
showed that it selectively induces apoptosis in human breast
cancer cells and inhibits tumor growth in nude mice. This gene
was downregulated in MCC (Table 2).
Another interleukin gene, IL23A, encodes a 19-kDa cytokine,
p19. IL23A and IL12 p40 (IL12B) constitute heterodimeric
IL23. Cytokines are soluble proteins that regulate cell
proliferation and differentiation and effector functions of
immune cells. Langowski et al. [29] have recently demonstrated
that expression of the heterodimeric cytokine IL23 is increased
in human tumors. As expected, IL23Awas upregulated in MCC
(Table 2).
Signal transducer and activator of transcription proteins are
latent cytoplasmic transcription factors [30]. STATs can be
divided into two groups according to their specific functions.
One group is made up of STAT2, STAT4, and STAT6, which are
activated by a small number of cytokines and play a distinct role
in the development of T cells and in IFN-γ signaling [31]. The
other group consists of STAT1, STAT3, and STAT5, which are
activated in different tissues by means of a series of ligands and
involved in IFN signaling [31]. STAT2 is a transcription factor
critical to the signal transduction pathway of type I interferons
such as IFN-α [32]. The cytoplasmic STAT2 is tyrosine
phosphorylated after IFN-α binds to cell surface receptors.
The tyrosine-phosphorylated STAT2 rapidly localizes to the
nucleus and acquires the ability to bind specific DNA targets in
association with two other proteins, STAT1 and IFN regulatory
factor-9 (IRF-9) [32]. STAT1, STAT3, and STAT5 have beenshown to be involved in oncogenesis, since they bring about the
activation of cyclin D1 and of c-Myc and Bcl-xl expression and
are involved in promoting cell-cycle progression and cellular
transformation and in preventing apoptosis [30,31,33]. How-
ever, the status of STAT2 in oncogenesis is not clear. STAT1 is
considered as a potential tumor suppressor, since it plays an
important role in growth arrest and in promoting apoptosis [31].
Interestingly, the STAT2 gene was found to be downregulated in
MCC (Table 2).
MCC is a rare eyelid tumor. This is the reason we have been
able to collect MCC samples from only four patients, with ages
ranging from 42 to 70 years, over the past several years. In
addition, the collection of normal age-matched eyelid tissue
samples as controls was extremely difficult. Therefore, we
directed our effort in collecting the normal eyelid tissues from
normal individuals who visited the hospital for eyelid surgery
for ectropion. With our tremendous effort over the past several
years, two normal eyelid tissue samples were collected from
two individuals, ages 50 and 65 years, who underwent eyelid
surgery for ectropion. We believe that these could be the reasons
that no similar studies have been attempted previously. As we
have used age-matched normal and tumor tissues, validated the
differential expression data for five genes using two normal and
four tumor samples, and functionally categorized the differen-
tially expressed genes, we believe that the present data are a true
representative of the genes whose expression differs between
normal and tumor tissues.
In summary, our microarray data provide interesting insights
into several genes and pathways that are dysregulated in MCC
for the first time. Functional analysis of these genes will lead to
a better understanding of the development and progression of
this tumor. Furthermore, the data presented here will not only
provide important information about the genesis of this tumor,
but will also facilitate the identification of candidate genes that
could be used as therapeutic targets for the treatment of patients
with this tumor.
Materials and methods
Sample collection
A total of four MCC samples were ascertained from Minto Ophthalmic
Hospital, Bangalore. The age of the MCC patients ranged from 42 to 70 years.
MCCs were b10 mm in size and located in upper eyelids. Regional lymph node
metastasis was present in one of the MCC patients. MCC is known to be
associated with Muir–Torre syndrome, but none of the patients in the present
study were diagnosed with this syndrome. Two normal eyelid tissue samples
were collected from two individuals, ages 50 and 65 years, who underwent
eyelid surgery for ectropion. Tumor and normal tissue samples were obtained
either as surgically resected tissue or as biopsy samples. Normal and tumor
samples were stored in liquid nitrogen following surgery and then in a −80 °C
freezer for long-term storage. This research followed the tenets of the
Declaration of Helsinki and informed consent for research was obtained from
all individuals enrolled in the study.
Microarray analysis
Total RNAwas isolated from normal and tumor tissues using the Tri reagent
(Sigma–Aldrich, St. Louis, MO, USA) according to the manufacturer's
instructions. Total RNA was further purified on RNeasy Protect minikit
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formaldehyde agarose gel as described by Sambrook and Russell [34]. RNAwas
quantitated spectrophotometrically by measuring the absorbance at 260/280 nm.
Human 8K cDNA microarray slides (University Health Network, Toronto, ON,
Canada) were used for expression profiling of MCC. Human 8K arrays contain
∼8000 human genes. cDNA synthesis, labeling, hybridization, and detection of
signals were carried out using the Micromax TSA Labeling and Detection Kit
(Perkin–Elmer Life Sciences, Boston, MA, USA) according to the manufac-
turer's instructions. Due to the collection of very small tissue samples, which
yielded minute quantities of RNA samples, and the rarity of the tumor and the
availability of only two normal eyelid tissue samples, we were able to perform
only two microarray hybridizations. Each microarray hybridization experiment
was carried out using RNA samples from one normal and one tumor sample. In
this way, we used two different normal and two different tumor samples for two
hybridization experiments. After signal amplification, hybridized microarray
slides were dried and scanned using the GenePix Personal Scanner 4100A
(Molecular Devices, Union City, CA, USA). Image analysis and data extraction
were carried out using the GenePix Pro 3.0 program (Molecular Devices). Raw
data were normalized by grid-wise normalization [35]. Normalization was done
using the following formulae [36]. For each grid, calculation of normalization
factor= (sum of channel 1 intensity)/(sum of channel 2 intensity) (excluding
control and non-array-specific spots), calculation of raw ratio for each spot=
(channel 1 intensity)/(channel 2 intensity), and calculation of normalization ratio
for each spot=(raw ratio)/(normalization factor). Likewise, ratio was calculated
for spots in each grid separately [36]. Genes were considered to be upregulated
when the mean of the normalized ratios was ≥2. Genes were considered to be
downregulated when the mean of the normalized ratios was ≤0.5. Genes were
selected as significantly altered if they showed a similar pattern of expression
across two different experiments. For example, an upregulated gene showed
upregulation in both microarray experiments. A downregulated gene showed
downregulation in both microarray experiments. Differentially regulated genes
were taken along with the fold change values across the experiments. The scatter
plot of the log-ratios of experiment 1 and experiment 2 was generated using the
Microsoft Excel program to evaluate the performance and the concordance of
the two hybridization experiments (Supplemental Fig. 1S). Biological
significance of differentials was computed and functionally classified using
the GeneSpring GX software (Agilent Technologies, USA) on the basis of gene
ontology. The pathways were obtained using enrichment analysis based on gene
ontology categories using the GeneSpring GX software. GeneSpring GX
software depicts the biologically significant ontology for any given gene list as
follows: number of genes in the array known to be present in the ontology
category vs number of genes in the array that are differentially regulated.
Semiquantitative RT-PCR
We used semiquantitative RT-PCR analysis to validate the microarray data
for five genes in tumor samples using first-strand cDNA samples as templates.
First-strand cDNAwas synthesized with 1 μg total RNA from each sample using
the Revertaid H Minus First Strand cDNA Synthesis kit (MBI Fermentas,
Burlington, ON, Canada) according to the manufacturer's instructions. RT-PCR
primer sets were designed for each gene using gene sequences from the
GenBank database. Forward and reverse primers were selected from two
different exons of a gene to rule out the possibility of amplification of
contaminating genomic DNA. The GenBank accession numbers for the
GTF2H4, RBM12, UBE2D3, DDX17, LZTS1, and GAPDH genes are
BC004935, AJ289772, U39318, AK024985, BC075006, and AF261085,
respectively. Primer sequences for these genes are as follows: GTF2H4, F, 5′-
GGACTGAACCGAGTACACCTACAATG-3′, R, 5′-CCTGTGGCAAAGGC-
TGCTCCAGAA-3′; RBM12, F, 5′-AGGATTGACTTGGCCTCTACTTCTTG-
3′, R, 5′-CATCAGGAATGGTCAATCCAGAGAAG-3′; UBE2D3, F,
5′-TGACAGCCCATATCAAGGCGGTGTA-3′, R, 5′-ATTGTTAAAG-
CAGGCGACCACTGTGA-3′; DDX17, F, 5′-GTGTTGAGATCTGCATAGC-
CACTCC-3′, R, 5′-ACTCCACATCAGTGTCTGCCTATCA-3′; LZTS1, F,
5′-TCATGCCCTTCTCCAATCAGCTAGA-3′, R, 5′-TCCTGCTCCTTGG-
GCTTGTCTGGA-3′; and GAPDH, F, 5′-GTCATCCATGACAACTTTG-3′,
R, 5′-GTCATACCAGGAAATGAGC-3′. PCR was carried out in a total volume
of 25 μl containing 1 μl of first-strand cDNA template, 1.5 mMMgCl2, 200 μM
each dNTP, 1× buffer, and 1 U of Taq DNA polymerase (Sigma–Aldrich) usinga PTC-100 thermocycler (MJ Research, Inc., Waltham, MA, USA). PCR
conditions were as follows: an initial denaturation at 95 °C for 2 min was
followed by 18–25 cycles of denaturation at 95° C for 30 s, annealing at 55–
60 °C for 30 s, extension at 72° C for 1 min, with a final extension at 72°C for
5 min. RT-PCR primer sets for the GTF2H4, RBM12, UBE2D3, DDX17,
LZTS1, and GAPDH genes amplified 184-, 168-, 174-, 188-, 166-, and 458-bp
PCR fragments, respectively. For each gene, the PCR protocol was optimized to
obtain amplification in a linear range. Expression of GAPDH served as a
normalizing control. Following electrophoresis of RT-PCR products in 2%
agarose gels containing ethidium bromide, images of gels were acquired with a
Kodak CCD camera and quantification of the band intensity was performed by
densitometric analysis using the Kodak Digital Science Image Station Imaging
software version 3.6.1. Final data were expressed in arbitrary units (relative
expression) as a ratio of normal/GAPDH and tumor/GAPDH and plotted using
the GraphPad Prism software version 3.00 (GraphPad Prism software, San
Diego, CA, USA). The significance of differences in mRNA expression levels
between normal and tumor samples for each gene was assessed by two-tailed
unpaired Student's t test and the results were expressed as means±SEM [37]. A
probability value of p b 0.05 was considered significant. Semiquantitative RT-
PCR for each gene was performed in duplicate.
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